Expanded Strategic Partnership Enables Additional U.S. Manufacturing Capacity to Serve Increased Demand for Pharma/Biotech Customers

Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science,  announced the completion of its acquisition of Sanofi’s state-of-the-art sterile fill-finish and packaging site in Ridgefield, New Jersey, marking an expansion of the companies’ strategic partnership to enable additional U.S. drug product manufacturing. The terms of the deal were not disclosed. The Ridgefield facility is now part of Thermo Fisher's pharma services business within its Laboratory Products and Biopharma Services segment.

Under the agreement, Thermo Fisher will continue to manufacture a portfolio of therapies for Sanofi at the Ridgefield site while expanding use of the site to meet the growing demand for U.S. manufacturing capacity from pharma and biotech customers.

“We are excited to add Sanofi’s Ridgefield site to our network and welcome more than 200 highly experienced colleagues to Thermo Fisher,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher. “Bringing this world-class facility and team into our network strengthens our U.S. manufacturing capabilities to better support pharmaceutical and biotech customers, while positioning us for future expansion."

Thermo Fisher operates a leading global sterile fill-finish manufacturing network and now adds Ridgefield to its U.S. sites in Greenville, North Carolina and Plainville, Massachusetts. These sites are integral to the company’s Accelerator™ Drug Development 360° CDMO and CRO solutions, transforming the pharmaceutical value chain for emerging biotech and biopharma companies to speed life-changing medicines to patients.